Literature DB >> 18704710

Estimating key parameters in FOBT screening for colorectal cancer.

Dongfeng Wu1, Diane Erwin, Gary L Rosner.   

Abstract

OBJECTIVES: The association between screening sensitivity, transition probability, and individual's age in FOBT for colorectal cancer are explored, for both males and females.
METHODS: We apply the statistical method developed by Wu et al. [1] using the Minnesota colorectal cancer study group data, to make Bayesian inference for the age-dependent screening test sensitivity, the age-dependent transition probability from disease-free to preclinical state, and the sojourn time distribution, for both male and female participants in a periodic screening program. This gives us more information on the effectiveness of the fecal occult blood test in colorectal cancer detection.
RESULTS: The sensitivity appears to increase with age for both genders. However, the posterior mean sensitivity is not monotonic with age for males; it has a peak around age 74. The standard errors of the sensitivity are not monotone either; there is a minimum at age 69 for males and at age 78 for females. The age-dependent transition probability is not a monotone function of age; it has a single maximum at age 72 for males and a single maximum at age 75 for females. The age dependency seems more dramatic for females than for males. The posterior mean sojourn time is 4.08 years for males and 2.41 years for females, with a posterior median of 1.66 years for males and 1.88 years for females. The 95% highest posterior density (HPD) interval is (0.97, 20.28) for males and (1.15, 5.96) for females, which are very large ranges, especially for males. The reason might be that there were fewer men than women in the annual screening program.
CONCLUSION: Reliable estimates of age-dependent sensitivity and transition probability are of great value to policy-makers regarding the initial age for colorectal cancer screening exams. We found that the mean sojourn time for males is much longer than that for females, which may imply that FOBT screening for colorectal cancer may be more effective for males than for females.

Entities:  

Mesh:

Year:  2008        PMID: 18704710      PMCID: PMC2773467          DOI: 10.1007/s10552-008-9215-9

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  7 in total

1.  Colorectal cancer screening for persons at average risk.

Authors:  William F Anderson; Kate Z Guyton; Robert A Hiatt; Sally W Vernon; Bernard Levin; Ernest Hawk
Journal:  J Natl Cancer Inst       Date:  2002-08-07       Impact factor: 13.506

2.  Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.

Authors:  T R Church; F Ederer; J S Mandel
Journal:  J Natl Cancer Inst       Date:  1997-10-01       Impact factor: 13.506

3.  Offering patients colorectal cancer screening.

Authors:  Timothy R Church
Journal:  J Natl Cancer Inst       Date:  2005-03-02       Impact factor: 13.506

4.  MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle Broemeling
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

5.  Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.

Authors:  T C Prevost; G Launoy; S W Duffy; H H Chen
Journal:  Am J Epidemiol       Date:  1998-09-15       Impact factor: 4.897

6.  Estimation of the duration of a pre-clinical disease state using screening data.

Authors:  S D Walter; N E Day
Journal:  Am J Epidemiol       Date:  1983-12       Impact factor: 4.897

7.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

Authors:  J S Mandel; T R Church; F Ederer; J H Bond
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

  7 in total
  5 in total

1.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

2.  Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.

Authors:  Wenying Zheng; Carolyn M Rutter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-21       Impact factor: 4.254

3.  A projection of benefits due to fecal occult blood test for colorectal cancer.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Cancer Epidemiol       Date:  2009-09-04       Impact factor: 2.984

4.  Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age.

Authors:  Shawn A Ritchie; Doug Heath; Yasuyo Yamazaki; Bryan Grimmalt; Amir Kavianpour; Kevin Krenitsky; Hoda Elshoni; Ichiro Takemasa; Masakazu Miyake; Mitsugu Sekimoto; Morito Monden; Takeshi Tomonaga; Hisahiro Matsubara; Kazuyuki Sogawa; Kazuyuki Matsushita; Fumio Nomura; Dayan B Goodenowe
Journal:  BMC Gastroenterol       Date:  2010-11-29       Impact factor: 3.067

5.  Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?

Authors:  Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Arjen P Visscher; Jochim S Terhaar sive Droste; Pieter Scholten; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder; Leo G M van Rossum; Veerle M H Coupé
Journal:  BMC Gastroenterol       Date:  2014-12-21       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.